Buprenorphine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Buprenorphine Access in 2026

Despite landmark policy changes — the elimination of the X-waiver in January 2023 and the finalization of permanent telehealth prescribing rules in 2025 — Buprenorphine access remains a persistent challenge for patients with opioid use disorder (OUD). This briefing covers the current state of availability, prescribing implications, and practical tools to support your patients.

If you're looking for actionable steps to help patients locate Buprenorphine, see our companion guide: How to Help Your Patients Find Buprenorphine in Stock.

Timeline: Key Policy Changes

• 2002: Buprenorphine classified as Schedule III; DATA 2000 waiver (X-waiver) created for office-based prescribing
• 2020-2023: COVID-era telehealth flexibilities allowed telephonic Buprenorphine prescribing
• January 2023: MAT Act eliminates X-waiver requirement — all DEA-registered practitioners can prescribe Buprenorphine
• 2023: FDA approves Brixadi (extended-release subcutaneous Buprenorphine injection) for OUD
• 2025: DEA and HHS finalize permanent telemedicine rules for Buprenorphine, allowing initiation and 6-month supply via telehealth (including audio-only)
• 2025: USC Schaeffer Center study confirms most pharmacies still don't stock Buprenorphine despite expanded prescribing

Prescribing Implications

Who Can Prescribe

As of 2023, any practitioner with a standard DEA registration (Schedule III authority) can prescribe Buprenorphine for OUD. This includes physicians, nurse practitioners, physician assistants, certified nurse-midwives, clinical nurse specialists, and certified registered nurse anesthetists. No special waiver, additional DEA number, or patient cap applies.

Telehealth Prescribing

The 2025 final rule makes telehealth Buprenorphine prescribing permanent. Key provisions:

• Patients can initiate Buprenorphine via audio-visual or audio-only telehealth
• Up to a 6-month supply can be prescribed through telehealth before an in-person visit is required
• All standard prescribing requirements (PDMP checks, state regulations) still apply
• This is specific to Buprenorphine — other Schedule III-V controlled substances may have different telehealth rules

8-Hour Training Requirement

While the X-waiver is gone, prescribers who obtained their DEA registration after June 2023 must complete a one-time, 8-hour training on substance use disorders as part of their DEA registration or renewal. This is a training requirement, not a waiver application.

The Availability Picture

The core challenge in 2026 is not manufacturing supply — it's pharmacy-level stocking decisions.

The Data

• ~40% of Walmart, CVS, and Rite Aid locations decline to stock Buprenorphine (STAT News, 2024)
• Most pharmacies still don't carry Buprenorphine despite relaxed prescribing rules (USC Schaeffer Center, September 2025)
• Rural pharmacies are disproportionately affected
• Independent pharmacies are generally more willing to stock Buprenorphine than chains

Why Pharmacies Don't Stock It

• DEA regulatory burden and audit risk for controlled substances
• Theft and diversion concerns
• Stigma around OUD treatment
• Low demand perception (self-fulfilling cycle: pharmacies don't stock it → patients go elsewhere → pharmacy perceives low demand)
• Reimbursement challenges with some payers

40,339+ patients found their medications in stock

40K+

Find Buprenorphine In Stock Today →

Cost and Access Landscape

Understanding cost barriers is essential for treatment retention:

• Generic sublingual Buprenorphine: $45-$130/month with discount coupons; $100-$400/month cash price
• Brand Suboxone film: $400-$600/month without insurance
• Sublocade injection: $1,500-$1,900/month (typically covered by insurance)
• Brixadi injection: Comparable to Sublocade pricing; manufacturer savings available

Insurance coverage: Most commercial plans and Medicaid cover generic Buprenorphine/Naloxone. Prior authorization is commonly required. Many state Medicaid programs mandate coverage of all FDA-approved OUD medications without prior auth or copay. Medicare Part D covers Buprenorphine products.

Patient assistance: Indivior's INSUPPORT program provides copay assistance for Suboxone and Sublocade. Braeburn offers savings programs for Brixadi. For uninsured patients, NeedyMeds, RxAssist, and state-funded programs can help. The SAMHSA helpline (1-800-662-4357) provides free referrals.

Tools and Resources for Providers

Medfinder for Providers

Medfinder helps providers and their staff quickly identify pharmacies that have Buprenorphine in stock, reducing failed fill attempts and treatment interruptions. Consider integrating a pharmacy availability check into your prescribing workflow.

SAMHSA Resources

• SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
• SAMHSA OTP Directory: For patients who may benefit from Methadone as an alternative
• SAMHSA Buprenorphine Practitioner Locator: Helps patients find prescribers

Long-Acting Formulations as a Strategy

For patients with chronic pharmacy access issues, transitioning to Sublocade or Brixadi injectable formulations can eliminate pharmacy barriers entirely. These are administered in your office or clinic, improving treatment retention and reducing diversion risk.

Skip the calls, skip the stress.

Find Buprenorphine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Looking Ahead

The regulatory landscape for Buprenorphine has improved dramatically since 2020. The remaining barriers are largely structural — pharmacy stocking culture, stigma, and geographic disparities. As providers, we can help by:

• Establishing relationships with pharmacies that reliably stock Buprenorphine
• Proactively communicating pharmacy options to patients at the point of prescribing
• Offering long-acting injectable formulations when appropriate
• Advocating for state-level pharmacy stocking requirements
• Using tools like Medfinder to keep patients connected to medication access

Final Thoughts

Buprenorphine remains the gold standard for office-based OUD treatment, with an unmatched safety profile and the broadest prescribing access of any OUD medication. The gap between prescribing ease and pharmacy availability is the defining challenge of 2026.

By incorporating pharmacy availability tools, patient assistance resources, and long-acting formulations into your practice, you can help close that gap for your patients. Visit medfinder.com/providers to get started.